Amphastar Pharmaceuticals Inc  

(Public, NASDAQ:AMPH)   Watch this stock  
Find more results for MERCK SHARP & DOHME CORP.�
-0.08 (-0.77%)
After Hours: 10.31 0.00 (0.00%)
Oct 20, 5:02PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.20 - 10.86
52 week 6.67 - 12.52
Open 10.40
Vol / Avg. 74,943.00/134,932.00
Mkt cap 463.85M
P/E     -
Div/yield     -
EPS -0.03
Shares 44.64M
Beta     -
Inst. own 9%
Aug 12, 2014
Q2 2014 Amphastar Pharmaceuticals Inc Earnings Call
Aug 12, 2014
Q2 2014 Amphastar Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -2.41% 5.16%
Operating margin -2.39% 7.61%
EBITD margin - 13.36%
Return on average assets -1.28% 3.55%
Return on average equity -1.76% 4.89%
Employees 1,217 -
CDP Score - -


11570 6th St
United States - Map
+1-909-9809484 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Amphastar Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling technically challenging generic and injectable and inhalation products. The Company�s generic product candidates at various development stages that leverage its various technical capabilities, including injectable technologies, including various delivery methods and sizes of pre-filled syringes, vials in solution, suspension and lyophilized forms; inhalation technologies, including metered dose inhalers (MDIs) and metered dose inhalers (DPIs); and analytical technologies. As of May 20, 2014, the Company manufactures and sells 15 products in the United States and is developing a portfolio of 13 generic and seven injectable and inhalation product candidates. In addition to its marketed products, it has a pipeline of 20 generic and product candidates in various stages of development which target a variety of indications.

Officers and directors

Mary Ziping Luo Ph.D Chief Operating Officer, Chief Scientist and Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Jason B. Shandell J.D President, Director
Age: 40
Bio & Compensation  - Reuters
Jack Yongfeng Zhang Ph.D. Chief Executive Officer, Chief Science Officer, Director
Age: 67
Bio & Compensation  - Reuters
William J. Peters Chief Financial Officer, Senior Vice President, Treasurer
Age: 45
Bio & Compensation  - Reuters
Diane Gerst President, Amphastar Nanjing Pharmaceuticals Co., Ltd
Age: 54
Bio & Compensation  - Reuters
Marilyn J. Purchase Corporate Executive Vice President of Operations and President, International Medication Systems, Ltd.
Age: 64
Bio & Compensation  - Reuters
Richard Koo CPA Independent Director
Age: 73
Bio & Compensation  - Reuters
Howard S. Lee Ph.D. Independent Director
Age: 51
Bio & Compensation  - Reuters
Floyd F. Petersen Independent Director
Age: 70
Bio & Compensation  - Reuters
Richard Prins Independent Director
Age: 57
Bio & Compensation  - Reuters